IDP 120

Drug Profile

IDP 120

Alternative Names: IDP120

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Valeant Pharmaceuticals International
  • Developer Ortho Dermatologics; Valeant Pharmaceuticals International
  • Class Antiacnes
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acne vulgaris

Most Recent Events

  • 27 Jul 2017 Valeant Pharmaceuticals International acquired Ortho Dermatologics in 2011 and changed the name of the later to Valeant Dermatology. Subsequently, in July 2017, it was rebranded to Ortho Dermatologics
  • 16 Mar 2017 Valeant Pharmaceuticals plans a phase III trial for Acne vulgaris in 2017 (Valeant Pharmaceuticals pipeline, March 2017)
  • 01 Jun 2016 Valeant Pharmaceuticals initiates a phase Ib trial for Acne vulgaris (In adolescents, In children) in USA (Topical) (NCT02850003)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top